Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.
- FDA clears IND for NTI164 clinical program in the US
- US pharmacokinetic study to complement Australian Phase 3 trial
- Integrated data package supports global regulatory submissions
- Strengthened US patent portfolio enhances asset protection
- Ongoing strategic discussions with potential partners
FDA Clearance Marks Key Regulatory Milestone
Neurotech International (ASX:NTI) has taken a significant step forward by securing US Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for NTI164. This green light authorises the company to initiate clinical development in the US, marking a formal regulatory pathway outside its home market.
The IND clearance reflects the FDA’s review and acceptance of Neurotech’s comprehensive chemistry, manufacturing and controls (CMC), non-clinical, and clinical data package. While the company has yet to announce a definitive start date for US trials, the clearance itself is a prerequisite to advancing the program stateside.
US Pharmacokinetic Program to Complement Australian Phase 3 Trial
The US clinical program under the IND will focus on a population pharmacokinetic (PopPK) study, designed to generate vital data on how NTI164 behaves in the body. This approach is intended to dovetail with Neurotech’s ongoing Australian Phase 3 "Beyond Harmony" trial, which targets efficacy and safety in paediatric patients with Autism Spectrum Disorder (ASD).
By combining efficacy and safety data from Australia with pharmacokinetic insights from the US, Neurotech aims to build an integrated global clinical evidence package. This coordinated strategy is crafted to support future regulatory submissions and streamline product registration across jurisdictions.
Global Strategy Supported by Regulatory Engagement and IP Strengthening
Neurotech is actively engaging with both the FDA and the Australian Therapeutic Goods Administration (TGA) to harmonise its regulatory pathways. The company is leveraging these interactions to maximise the utility of clinical data across multiple markets, potentially accelerating global registration.
Adding to its strategic momentum, Neurotech recently secured Notices of Allowance for key US patent applications covering NTI164, extending intellectual property protection through to 2042. This fortified IP position enhances the asset’s commercial appeal as the company pursues strategic partnerships.
NTI164’s Promise in Paediatric Neurological Disorders
NTI164 is a proprietary formulation rich in CBDA and minor cannabinoids, developed to address neuroinflammatory and immune dysregulation mechanisms implicated in neurodevelopmental conditions. Earlier clinical and preclinical studies have shown promising safety and efficacy signals in ASD and related disorders.
Neurotech’s Phase 3 trial, alongside the planned US PopPK study, aims to provide a robust data package that could underpin regulatory approvals and commercialisation in a market with significant unmet needs.
Bottom Line?
FDA clearance unlocks US clinical development, but the timing and success of subsequent trials remain crucial to advancing NTI164’s global registration ambitions.
Questions in the middle?
- When will Neurotech commence the US pharmacokinetic study under the IND?
- How will data from the US PopPK program influence dosing and regulatory approvals?
- What strategic partnerships might Neurotech secure leveraging its strengthened US IP portfolio?